These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19080736)

  • 1. Clinical implications of low-penetrance breast cancer susceptibility alleles.
    Freisinger F; Domchek SM
    Curr Oncol Rep; 2009 Jan; 11(1):8-14. PubMed ID: 19080736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
    Couch FJ; Sinilnikova O; Vierkant RA; Pankratz VS; Fredericksen ZS; Stoppa-Lyonnet D; Coupier I; Hughes D; Hardouin A; Berthet P; Peock S; Cook M; Baynes C; Hodgson S; Morrison PJ; Porteous ME; Jakubowska A; Lubinski J; Gronwald J; Spurdle AB; ; Schmutzler R; Versmold B; Engel C; Meindl A; Sutter C; Horst J; Schaefer D; Offit K; Kirchhoff T; Andrulis IL; Ilyushik E; Glendon G; Devilee P; Vreeswijk MP; Vasen HF; Borg A; Backenhorn K; Struewing JP; Greene MH; Neuhausen SL; Rebbeck TR; Nathanson K; Domchek S; Wagner T; Garber JE; Szabo C; Zikan M; Foretova L; Olson JE; Sellers TA; Lindor N; Nevanlinna H; Tommiska J; Aittomaki K; Hamann U; Rashid MU; Torres D; Simard J; Durocher F; Guenard F; Lynch HT; Isaacs C; Weitzel J; Olopade OI; Narod S; Daly MB; Godwin AK; Tomlinson G; Easton DF; Chenevix-Trench G; Antoniou AC;
    Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1416-21. PubMed ID: 17627006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer susceptibility and the functions of BRCA1 and BRCA2.
    Venkitaraman AR
    Cell; 2002 Jan; 108(2):171-82. PubMed ID: 11832208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic epidemiology of breast cancer genes.
    Thompson D; Easton D
    J Mammary Gland Biol Neoplasia; 2004 Jul; 9(3):221-36. PubMed ID: 15557796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    Osorio A; Rodríguez-López R; Díez O; de la Hoya M; Ignacio Martínez J; Vega A; Esteban-Cardeñosa E; Alonso C; Caldés T; Benítez J
    Int J Cancer; 2004 Jan; 108(1):54-6. PubMed ID: 14618615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer susceptibility-A new look at an old model.
    Peto J
    Cancer Cell; 2002 Jun; 1(5):411-2. PubMed ID: 12124169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
    Kleibl Z; Kristensen VN
    Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families.
    Fachal L; Santamariña M; Blanco A; Carracedo A; Vega A
    Clin Transl Oncol; 2013 Feb; 15(2):164-5. PubMed ID: 23150219
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
    Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
    Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
    Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
    Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.